ArticleNature immunology2024
Sepsis-trained macrophages promote antitumoral tissue-resident T cells.
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- CLEC-1 promotes early IFN response in cDC1s and favors immune dysregulation during sepsis in mice.iScience · 2026Article
- Macrophage heterogeneity in human secondary lymphoid organs.Clinical science (London, England : 1979) · 2026Review
- A portable nanobiosensor with machine learning: enabling multi-cytokines point-of-care testing and early identification of sepsis immunoparalysis.Journal of nanobiotechnology · 2026Article
- Therapeutic bacteria-trained NK cells confer long-term protection against cancer metastasis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Immunology of Sepsis.Clinics in chest medicine · 2026Review
- Molecular subtyping and immune microenvironment heterogeneity in pediatric influenza-associated prolonged multiple organ dysfunction syndrome.Translational pediatrics · 2026Article
- A gene-expression module identifies circulating immune cells with enhanced recruitment to sites of inflammation.iScience · 2026Article
- Review
- Recent perspectives on macrophage memory: types, mechanisms, and characteristics in pulmonary diseases.Cell communication and signaling : CCS · 2026Review
- High Mobility Group Protein B1 Promotes Interferon Regulatory Factor 1 SUMOylation to Prime Trained Immunity of Circulating Monocytes and Aggravate the Progressive Synovial Inflammation in Knee Osteoarthritis.Research (Washington, D.C.) · 2026Article
- Heat-killedFrontiers in immunology · 2026Article
- Bibliometric and Visual Analysis of Trained Immunity from 2005 to 2024.Journal of inflammation research · 2026Review
- A conserved monocyte activation program links brain injury to systemic immune adaptation and clinical outcomes.Frontiers in immunology · 2026Article
- Mitochondrial regulation of lactylation in sepsis-induced cardiomyopathy.Critical care (London, England) · 2025Review
- Trained Immunity in Health and Disease.MedComm · 2025Review
- Trained immunity: induction of an inflammatory memory in disease.Cell research · 2025Review
- Positive and negative roles of myeloid cells in cancer immunotherapy.Journal for immunotherapy of cancer · 2025Review
- β-Glucan reprograms alveolar macrophages via neutrophil/IFNγ axis in a murine model of lung injury.eLife · 2025Article
- Complement Proteins Identify Rapidly Progressive Diabetic Kidney Disease.Kidney international reports · 2025Article
- Trained immunity in chronic inflammatory diseases and cancer.Nature reviews. Immunology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
33 authors.
Funding
Abstract
Sepsis induces immune alterations, which last for months after the resolution of illness. The effect of this immunological reprogramming on the risk of developing cancer is unclear. Here we use a national claims database to show that sepsis survivors had a lower cumulative incidence of cancers than matched nonsevere infection survivors. We identify a chemokine network released from sepsis-trained resident macrophages that triggers tissue residency of T cells via CCR2 and CXCR6 stimulations as the immune mechanism responsible for this decreased risk of de novo tumor development after sepsis cure. While nonseptic inflammation does not provoke this network, laminarin injection could therapeutically reproduce the protective sepsis effect. This chemokine network and CXCR6 tissue-resident T cell accumulation were detected in humans with sepsis and were associated with prolonged survival in humans with cancer. These findings identify a therapeutically relevant antitumor consequence of sepsis-induced trained immunity.
Indexed as
Identifiers
38684922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.